Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;7(Suppl 4):S370-S372.
doi: 10.21037/tlcr.2018.09.18.

Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Francesca Casaluce  1 , Cesare Gridelli  1
Affiliations
Editorial

Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Francesca Casaluce et al. Transl Lung Cancer Res. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Gridelli received honoraria as speaker bureau and advisory board member from Astra Zeneca, BMS, MSD and Roche. The other author has no conflicts of interest to declare.

Comment in

Comment on

References

    1. Borghaei H, Paz-Arez L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Non squamous Non-Small Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. Gainor JF, Shaw AT, Sequist LV, et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis. Clin Cancer Res 2016;22:4585-93. 10.1158/1078-0432.CCR-15-3101 - DOI - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New Engl J Med 2015;372:2018-28. 10.1056/NEJMoa1501824 - DOI - PubMed
    1. Hellmann MD, Garon EB, Gandhi L, et al. MINI03.05 Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC. J Thorac Oncol 2015;10:S261-406.
    1. Lee CK, Man J, Lord S, et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma. A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:210-6. 10.1001/jamaoncol.2017.4427 - DOI - PMC - PubMed